Abstract
Inhibition of growth stimulatory pathways has emerged as a major focus of targeted cancer drug development. New insights regarding potent, transient inhibition of cell signaling may challenge the dogma of medicinal chemistry and clinical trial design.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
